- Our World
- Our Business
- Life at Lupin
- Global Sites
Active pharmaceutical ingredients (APIs) are entrenched in the foundations of Lupin and are a backbone to the organization.
Historically, along with being one of the most vertically integrated pharmaceutical companies Lupin has also consciously focused on building scale and efficiencies-making it an undisputed leader in its chosen product segments.
Lupin has remained a global leader in therapeutic segments such as Cephalosporins, Cardiovascular and the Anti-TB space for over 15 years.
For the FY 2015 revenue from our API business was Rs.11,941 million as compared to Rs.9,498 million in FY 2013, growing at a CAGR of 12 % despite price pressures.
The Company has re-focused its API group into making further inroads into markets such as US, Europe, Japan and exploring new opportunities in emerging markets like China, Brazil, Mexico, Korea and Russia.
As part of its new growth plan Lupin’s API business targets on developing 4-6 new APIs per quarter with renewed focus & investment on API R&D.